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ABSTRACT 
Infection with high risk oncogenic human papillomavirus (HPV) such as HPVs 16 and 18 is the main cause of cervical 
cancer. The objective of this study was to determine the impact of Chlamydia trachomatis, Herpes simplex virus 2 (HSV 2), 
Treponema pallidum and some sexual behaviour on malignant progression of cervical lesion in Douala, Cameroon. From 
July 2009 to January 2010, we performed routine cervical smears to 163 consenting women, who completed a questionnaire 
on risk factors of cervical cancer. Blood samples were obtained for each of these women and used for the detection of 
antibodies against Chlamydia trachomatis, HSV 2 and Treponema pallidum. Results obtained showed that 26/163 (17 LSIL 
and 9 HSIL) of women had abnormal cytology, 75.5% (123/163) had HSV 2 infection, 19% (31/163) infected by Chlamydia 
trachomatis and 4.3% (7/163) infected by Treponema pallidum. Among the LSIL-positive women 35.3% (6/17) and 94.1% 
(16/17) were infected with Chlamydia trachomatis and HSV 2 respectively. Among those with HSIL cytology, 22.2% (2/9), 
66.7% (6/9) and 11.1% (1/9) respectively had Chlamydia trachomatis, HSV 2 and Treponema pallidum. High parity and 
pregnancy rate was observed among women with positive cytology. Our finding shown high rate of cervical abnormalities 
among women infected with HSV 2; and among those with a higher number of parities and pregnancies. These results 
suggest that further investigations should be made in Cameroon to access real burden of these risk factors in the 
progression and persistence of cervical lesion. 
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INTRODUCTION    
The genital infection by the human papillomavirus 
(HPV) is a sexually transmitted infection most 
common, known today as the main cause of cervical 
cancer in women (1). Epidemiological and 
molecular investigations have shown that more 
than 120 different genotypes of this virus have been 
identified and 40 were recognized as being able to 
infect the anogenital mucosa (2). Several study are 
demonstrated that only 18 of these type are 
considered as high risk oncogenic for the cervix, and 
12 (HPVs 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59) 
so as well established, with predominance of HPVs 
16 and 18 (3,4,5). The study of genome organization, 
regulation of gene expression and protein 
characterization has allowed understanding the 
mechanisms of carcinogenesis associated with these 
viruses (6,7). Their involvement in the malignant 
transformation of cervix was recognized as serious 
problem of health in developing countries (8). Many 
authors’ reports that, in most cases, particularly 
among women under 30 years, HPV infections are 
transient and only a small percentage of infection 
persist and may progress to neoplasic cervical 
lesion. Viral clearance of HPV is quite fast and 
frequent, on average 70% of infections regress in 12 
months and 90% in 24 months (9).  
The raison of variable period of latency observed in 
some women remain poorly understood, but it has 
been generally accepted that other factors contribute 
to the spread and persistence of precancerous 
cervical lesion. Among these factors, co-infection 
with multiple HPV types, viral load, immune 
deficiency, active smoking, multiparity, multiple 
sexual partners, early sexual intercourse, excessive 
use of hormonal contraceptive and other sexually 
transmitted infections (STI) have been investigated 
as potentially involved in the transformation of 
epithelial cells of the cervix. These factors greatly 
increase likelihood of developing cervical neoplasic 
lesion (10). Among, STI studied we have infection 
with Herpes simplex virus type 2 (HSV 2), Chlamydia 
trachomatis (C. trachomatis) and Treponema pallidum 
(T. pallidum). These pathogen agents are spread 
sexually, causing considerable morbidity and 
socioeconomic problems in several countries. HSV 2 
infects the genital mucosa and establishes a life-long 
infection in sensory ganglia, and it is the most 
common cause of genital ulcers. 
Seroepidemiological data from worldwide studies 
performed during the last decade have estimated 
the HSV 2 seroprevalence to range from 0 % in 
children to more than 80 % in selected populations 





(11,12). Infection with C. trachomatis is the most 
prevalent bacterial STI causing symptomatic and, 
more commonly, asymptomatic genital infection. In 
women, C. trachomatis is an important cause of 
cervicitis and salpingitis as well as pelvic 
inflammatory disease (13). T. pallidum is the 
etiologic agent of syphilis. This microorganism is 
transmitted during sexual activity from a 
mucocutaneous lesion. In acquired infection, after 
an initial incubation period of 3 – 90 days, a solitary 
papule with spirochaetes, erupts at the site of 
inoculation, which is often found on the genitalia, 
and less frequently on the rectal mucosa. The 
fundamental histological changes in acquired 
syphilis are vasculitis and its consequences, necrosis 
and fibrosis (14).   
 
The objectives of the present study were to 
determine the impact of Chlamydia trachomatis, 
Treponema pallidum and Herpes simplex virus 2 (HSV 
2) on the malignant transformation of epithelial cells 
of cervix and also, to evaluate some behavioural 
factors involved in the natural history of cervical 
lesion in Douala, Cameroon. 
 
MATERIALS AND METHODS  
Study population 
From July 2009 to January 2010, a total of 163 
women were enrolled simultaneously in two health 
centre of Douala (Cameroon). Informed consent was 
obtained from all women and study was approved 
by national ethic committee. Women were eligible 
in the study if they were aged 17 and over, married 
or unmarried, were not pregnant and not had 
intercourse 48 hours before. All women were not 
menstruating and had not made a vaginal washing 
at time of diagnosis. They completed a structured 
questionnaire including number of sexual partners, 
parity, abortion, age of first sexual intercourse and 
the number of pregnancies. 
 
Sample collection 
During their visit to a gynaecologist, cervical smear 
was performed for early detection of cervical lesion. 
Results obtained were classified according to the 
Bethesda system; as negative, atypical squamous 
cell of undetermined significance (ASCUS), low 
squamous cell intraephithelial lesion (LSIL) and 
high squamous cell intraepithelial lesion (HSIL) 
(15). All pap smears were analyzed independently 
by two pathologists and the final result was based 
on a consensus between of both. Blood sample were 
obtained by venipuncture and centrifuged at 4000 
rpm for 10 min and serum obtained was store at – 
30 °C for detection of antibodies against Chlamydia 
trachomatis, HSV 2 and Treponema pallidum. 
 
Detection of Chlamydia trachomatis, HSV 2 and 
Treponema Pallidum 
C. trachomatis IgG Enzyme-linked immunosorbent 
assay (ELISA) from DRG Diagnostics laboratory 
was used for the detection of specific IgG antibodies 
against C. trachomatis. The assay was carried out as 
described previously by Piura et al., 1985 (16). 
Immunoglobulin G antibodies to HSV 2 were 
determined by microtest-plate ELISA kits (Teco 
Diagnostics Laboratory, reference IGMH2G-96) 
using the general technical principles. Each sample 
was analyzed by indirect blocking ELISA protocol 
(17). The detection of antibodies to T. Pallidum was 
performed by the method of heamagglutination 
(18). Commercial Kit TPHA (Treponema pallidum 
heamagglutination assay) of Biomagrehb laboratory 
was used for this purpose. All manipulations were 
performed according to manufacturer’s instructions.  
 
Statistical analysis 
Statistical analysis were performed by SPSS 16.0 
software using chi squared test and T-student test. 
Statistical significance was accepted for P < 0.05.  
 
RESULTS 
This study investigated the impact of some sexually 
transmitted infection on cervical abnormalities, in 
163 consenting women randomly recruited in two 
health centre of Douala (Cameroon). Table 1 
summarize the incidence of some microbial 
infectious agents according to the cytology in the 
total population. The Pap smear results revealed 
that HSV 2 is the leading infection among women 
with 62 %, 9.8 % and 3.7 % for normal, LSIL and 
HSIL respectively while Chlamydia is the second 
with 14.1 %, 3.7 % and 1.2 %. T. Pallidum which 
count for 3.7 %, 0.0 % and 0.6 % for normal, LSIL 




















TABLE 1: INCIDENCE OF C. TRACHOMATIS, T. PALLIDUM AND HSV 2 ACCORDING TO THE CYTOLOGY 
IN TOTAL POPULATION 
 
Cytology 
Normal       LSIL a        HSIL b 
      Total           
[n/163]         (%)  [n/163]         (%)    [n/163]         (%) 
HSV 2     
      Positive 101/163       (62)  16/163         (9.8)    6/163         (3.7) 123/163 (75.5) 
       Négative   36/163      (22.1)  1/163           (0.6)    3/163         (1.8)                  40/163 (24.5) 
C. trachomatis  
     Positive 23/163        (14.1)  6/163           (3.7)    2/163         (1.2)   31/163 (19) 
      Négative 114/163      (69.9) 11/163          (6.7)    7/163         (4.3)          132/163 (81)              
T. pallidum  
          Positive  6/163          (3.7)  0/163           (0.0)     1/163        (0.6)       7/163  (4.3) 
   Négative 131/163      (80.4) 17/163        (10.4)     8/163        (4.9)     156/163 (95.7) 
     
Total 137/163      (84.1)     17/163        (10.4)     9/163        (5.5)     163/163 (100) 
  
(%): frequency, a: Low squamous cell intraepithelial lesion    b: High squamous cell intraepithelial lesion 
 
Table 2 presents the frequencies of C. trachomatis, T. 
pallidum and HSV 2 in women with positive 
cytology. The data shown that cervical 
abnormalities are high in women infected with HSV 
2: 94.1 % and 66.7 % for LSIL and HSIL respectively 
(vs 5.9 % and 33.3 % for LSIL and HSIL in women 
not infected).  Significant difference was found 
between HSV 2 positive and negative cases 
compared with chi squared test (P = 0,018). C. 
trachomatis was diagnosed in fewer percentages 
among positive women: 35.3 and 22.2 for LSIL and 
HSIL respectively and T. pallidum was detected in 
very low percentage positive women. The difference 
between negative and positive women is not 
significant for these two infectious agents.  
 






LSIL a (N = 17) 
 
          HSIL b (N = 9) 
P-value 
[n/17]      (%) [n/9]      (%) 
Infections 
 
     
C. trachmatis     0.134 NS 
                    Positive 6/17      (35.3) 2/9      (22.2)  
Négative 11/17      (64.7) 7/9      (77.8)      
      
HSV 2             0.018 * 
                    Positive 16/17     (94.1) 6/9      (66.7)  
Négative 1/17      (5.9) 3/9      (33.3)  
      
T. pallidum       0.161 NS 
                    Positive 0/17      (0.0) 1/9 (11.1)  
Négative 17/17     (100) 8/9 (88.9)  
      
 
(%): Frequency, *: statistical difference,  NS : No significant difference,  N: Total number. a: Low squamous cell intraepithelial 
lesion,  b: High squamous cell intraepithelial lesion. 
 
Table 3 represents variations of type G 
immunoglobulin of HSV 2 and Chlamydia in patients 
with abnormal cytology. We note that this index 
believes with severity of disease for C. trachomatis: 
0.6 ± 0.2 to 1.0 ± 0.2 respectively for LSIL and HSIL 
while it decreases for HSV 2 (4.4 ± 0.9 to 1.3 ± 0.2). 
The difference between LSIL and HSIL positive 
patients was statistically significant for HSV 2  















TABLE 3: VARIATION OF IMMUNOGLOBULIN G ANTIBODIES AGAINST HSV 2 AND C. 
TRACHOMATIS AMONG WOMEN WITH CERVICAL ABNORMALITIES 
 
 
SE = Standard Error, NS: No statistical difference, *: Statistical difference, N: Total number, a: Low squamous 
cell intraepithelial lesion,  b: High squamous cell intraepithelial lesion. 
 
Table 4 examines some risk factors that might 
involve in development of cervical lesion. The 
results revealed the higher percentage of cervical 
lesion in women aged ≤ 17 years old at first vaginal 
sex intercourse (64.7 % and 55.6 % for LSIL and 
HSIL respectively) compared to women aged > 17 
years old. No statistical difference was found for 
this factor between these two groups positive 
women. Regarding parity and pregnancy, we found 
a high rate of cervical abnormalities in women with 
a number of parity and pregnancy less than 3 and 
between 4 and 7:  82.4 % and 66.7 % for LSIL and 
HSIL for parity and 64.7 % and 66.7 % for 
pregnancy respectively. Significant statistical 
difference (P < 0.05) was observed in correlation 
with cervical abnormalities for these two factors
. 
 




LSIL a (N = 17) HSIL b (N = 9) 
χ2 trend (P –value) 
[n/17] (%) [n/9] (%) 
Factors  
AFVS C (years)                                                                                                       0.655 NS 
≤17 11/17     (64.7) 5/9 (55.6)  
>17 6/17     (35.3) 4/9 (44.4)  
Parity                                                                                                          0.003 * 
≤ 3 14/17 (82.4) 2/9 (22.2)  
4-7 3/17 (17.6) 6/9 (66.7)  
≥ 8 0/17 (0.0) 1/9 (11.1)  
Pregnancy                                                                                                          0.047 * 
≤ 3 6/17 (35.3) 1/9 (11.1)  
4-7 11/17 (64.7) 6/9 (66.7)  
≥ 8 0/17 (0.0) 2/9 (22.2)  
Abortion                                                                                                       0.215 NS 
0 3/17 17.6 4/9 44.4  
1-2 11/17 64.7 4/9 44.4  
>2 3/17 17.6 1/9 11.1  
 
(%): Frequency, NS: No statistical difference, *: Statistical difference, N: Total number,  a: Low squamous cell intraepithelial 
lesion,  b: High squamous cell intraepithelial lesion,  C: Age at first vaginal sex. 
 
DISCUSSION 
The persistent infection with a high-risk HPV is 
recognized as the principal factor for malignant 
progression of cervical lesion. However in some 
women infected since several years, there are no 
complications while others develop cancer. This 
finding suggests that other factors play an 
important role in the transformation process. The 
aim of our study was to investigate the role played 
by some sexually transmitted infection on the 
development of cervical lesion. Our results showed 
that HSV 2 positive patients are a higher risk of 
developing cervical lesion. Positive variation of 
index of immunoglobulin G antibodies against HSV 
2 was found among women with cervical 
abnormalities.  Similar results were reported in 
studies carried out in others sites (19,20,21). This 
observation reveals the role played by HSV 2 
 
LSIL a (N = 17) 
  
HSIL b (N = 9)  
 
 T-student test  (P-value) 






0.6 ± 0.2 
 
 
1.0 ± 0.2 
 
 
                  0.092 NS 





infection in the persistence and the development of 
cervical neoplasia. Our knowledge about the 
specific role of this pathogen agent in the 
development of cervical lesion is limited. There are 
several mechanisms by which HSV 2 may act, such 
as direct genotoxicity. The most likely biologic 
mechanism is the induction of cervical 
inflammation leading genotoxic damage through 
oxidative metabolites (22). Several studies have 
reported that the carcinogenic molecules (nitric 
oxide for instance) produced during the 
inflammatory response induced by this infection, 
ulcerative lesions of the infection, decrease of local 
immunity could explain the persistence of cervical 
lesion related to HPV infection and therefore the 
loss of viral clearance in patients (23,24). HSV 2 
infection increase susceptibility to HPV causing 
alterations of epithelial cells, thus facilitating the 
entry of HPV virions.  
 
In our study, no significant correlation was found 
between cervical abnormalities, C. trachomatis and T. 
pallidum. The frequencies of antibodies against C. 
trachomatis and anti-T. pallidum  are not high among 
women having cervical disease. Some previous 
epidemiological studies have produced the same 
results regarding association between cervical 
intraepithelial neoplasia and these two microbial 
infectious agents. However, others studies reported 
a positive association between C. trachomatis, T. 
pallidum and cervical lesion associated with HPV 
(25,26). Therefore, the effective role of these 
pathogens agents remain to be clarified. 
In the same context, our data showed positive 
association between multiple parities, pregnancies 
and the increased risk of cervical intraepithelial 
lesion. These results agree with others 
epidemiological studies relating to association 
between these risk factors and malignant 
progression of cervical lesion. Biochemical 
mechanisms for demonstrating the association 
between these factors and natural history of cervical 
lesion is not documented and remain poorly 
understood today. But, some authors suggest that 
hormonal change and traumatic producing during 
pregnancy and childbirth may explain the 
involvement of these factors in the development of 
cervical abnormalities (27,28). 
 
CONCLUSION 
The results obtained of this study suggest that HSV 
2 infection might increase risk of cervical 
intraepithelial lesion in our population. Multiple 
parities and pregnancies are also considerable 
factors involved in the development and 
progression of cervical abnormalities. Our data 
confirm and stress that the screening of cervical 
abnormalities are desirable for women who 
attending public and private health centre in Douala 
(Cameroon), to assess the future risks of cervical 
intraepithelial lesion and cervical cancer. More 
investigations should be made about of these risk 
factors to clarify their real impact in the progression 
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